特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
953429

医薬品用オメガ3脂肪酸の世界市場:業界の動向と2027年までの予測

Global Omega 3 Ingredients for Pharmaceuticals Market - Industry Trends and Forecast to 2027

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 378 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
医薬品用オメガ3脂肪酸の世界市場:業界の動向と2027年までの予測
出版日: 2020年07月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 378 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品用オメガ3脂肪酸の市場は、2020年から2027年まで11.0%のCAGRで成長を続けると予測されています。オメガ3脂肪酸には、ドコサヘキサエン酸(DHA)、エイコサペンタエン酸(EPA)、アルファリノレン酸(ALA)などがあり、心血管疾患、自己免疫疾患、骨疾患、関節疾患、神経疾患、眼科疾患、皮膚疾患、がんなどの治療薬の原料として用いられています。

当レポートは、世界の医薬品用オメガ3脂肪酸市場を調査したもので、新型コロナウイルス感染症(COVID-19)パンデミックの影響、原料別、タイプ別、形状別、治療領域別、患者タイプ別、流通チャネル別、地域別の分析、各社の勢力図、企業プロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場区分

第3章 エグゼクティブサマリー

  • 特許分析
  • 価格分析

第4章 規制

第5章 COVID-19パンデミックの影響

  • 価格への影響
  • 需要への影響
  • サプライチェーンへの影響
  • 各社の戦略的決定
  • 結論

第6章 市場の概要

  • 促進要因
    • オメガ3の健康上の利点に関する消費者の意識
    • 機能性食品とサプリメントの需要拡大
    • 認定された食品成分に対する選好度の上昇
    • ライフスタイルによる疾病増加に伴うオメガ3ベース製品の需要拡大
  • 抑制要因
    • オメガ3の成分の香りと味覚に関する消費者の否定的な認識
    • 製品の高コスト
  • 市場機会
    • オメガ3を得るための代替原料の研究開発
    • 植物ベースのオメガ3製品に対する消費者需要の高まり
    • オメガ3成分の濃度を高める技術の開発
  • 課題
    • 魚ベースの製品に関連する副作用とアレルギー
    • オメガ3 原材料の持続可能性の問題

第7章 原料別の市場分析

  • 概要
  • 魚類
  • 植物

第8章 タイプ別の市場分析

  • 概要
  • ドコサヘキサエン酸(DHA)
  • エイコサペンタエン酸(EPA)
  • アルファリノレン酸(ALA)

第9章 形状別の市場分析

  • 概要
  • 液体
  • 乾燥状態

第10章 治療領域別の市場分析

  • 概要
  • 心血管疾患
    • 高脂血症
    • 脳卒中
    • 高血圧
    • その他
  • がん
    • 前立腺がん
    • 乳がん
    • 結腸直腸がん
    • その他
  • 神経障害
    • アルツハイマー病
    • 認知障害
    • 双極性障害
    • 統合失調症
    • その他
  • 自己免疫疾患
    • 関節リウマチ
    • 全身性エリテマトーデス(SLE)
    • 1型糖尿病
    • その他
  • 骨と関節の障害
    • 骨粗鬆症
    • 関節炎
    • その他
  • 肌の健康
    • ニキビ
    • シワ
    • 肌の老化
    • その他
  • 眼科疾患
    • ドライアイ症候群
    • 加齢性黄斑変性症
    • その他
  • その他

第11章 患者タイプ別の市場分析

  • 概要
  • 成人
    • 女性
    • 男性
  • 小児

第12章 流通経路別の市場分析

  • 概要
  • 直接
  • 間接

第13章 地域別の市場分析

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • オランダ
    • イタリア
    • デンマーク
    • スウェーデン
    • スペイン
    • スイス
    • ロシア
    • ベルギー
    • トルコ
    • ポーランド
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • マレーシア
    • シンガポール
    • ベトナム
    • ニュージーランド
    • フィリピン
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 中東・アフリカ
    • 南アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • クウェート
    • その他

第14章 各社の勢力図

  • 世界市場のシェア分析
  • 北米市場のシェア分析
  • 欧州市場のシェア分析
  • アジア太平洋市場のシェア分析

第15章 SWOT分析

第16章 企業プロファイル

  • CRODA INTERNATIONAL PLC
  • CORBION
  • DSM
  • KD PHARMA GROUP
  • STRIDES PHARMA SCIENCE LIMITED
  • BASF SE
  • PHARMA MARINE AS
  • ABBVIE INC.
  • AMARIN CORPORATION
  • ANI PHARMACEUTICALS, INC.
  • ASTRAZENECA
  • AVESTIA PHARMA
  • CAMBER PHARMACEUTICALS, INC.
  • EPAX (A SUBSIDIARY OF PELAGIA AS)
  • FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG)
  • GLAXOSMITHKLINE PLC
  • KINOMEGA BIOPHARM INC
  • NOVASEP
  • SOLUTEX

第17章 アンケート

第18章 関連レポート

図表

LIST OF FIGURES

  • FIGURE 1 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 54
  • FIGURE 2 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION 57
  • FIGURE 3 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS 58
  • FIGURE 4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 59
  • FIGURE 5 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS 59
  • FIGURE 6 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS 60
  • FIGURE 7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID 62
  • FIGURE 8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS 63
  • FIGURE 9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 67
  • FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 68
  • FIGURE 11 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 69
  • FIGURE 12 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027 69
  • FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING REGION FOR OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 70
  • FIGURE 14 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY 71
  • FIGURE 15 PATENT REGISTERED BY YEAR (2000-2020) 72
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 81
  • FIGURE 17 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS) 85
  • FIGURE 18 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019 91
  • FIGURE 19 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS) 92
  • FIGURE 20 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027) 92
  • FIGURE 21 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE 93
  • FIGURE 22 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019 97
  • FIGURE 23 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS) 98
  • FIGURE 24 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027) 98
  • FIGURE 25 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE 99
  • FIGURE 26 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019 104
  • FIGURE 27 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS) 105
  • FIGURE 28 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027) 105
  • FIGURE 29 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE 106
  • FIGURE 30 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019 110
  • FIGURE 31 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS) 111
  • FIGURE 32 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 111
  • FIGURE 33 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 112
  • FIGURE 34 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019 125
  • FIGURE 35 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS) 126
  • FIGURE 36 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027) 126
  • FIGURE 37 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE 127
  • FIGURE 38 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019 131
  • FIGURE 39 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS) 132
  • FIGURE 40 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 132
  • FIGURE 41 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 133
  • FIGURE 42 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 138
  • FIGURE 43 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 139
  • FIGURE 44 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 139
  • FIGURE 45 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019 & 2027) 140
  • FIGURE 46 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 140
  • FIGURE 47 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 142
  • FIGURE 48 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 143
  • FIGURE 49 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 143
  • FIGURE 50 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 144
  • FIGURE 51 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 144
  • FIGURE 52 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 161
  • FIGURE 53 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 162
  • FIGURE 54 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 162
  • FIGURE 55 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 163
  • FIGURE 56 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 163
  • FIGURE 57 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 222
  • FIGURE 58 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 223
  • FIGURE 59 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 223
  • FIGURE 60 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 224
  • FIGURE 61 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE(2020-2027) 224
  • FIGURE 62 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 288
  • FIGURE 63 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 289
  • FIGURE 64 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 289
  • FIGURE 65 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 290
  • FIGURE 66 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 290
  • FIGURE 67 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 307
  • FIGURE 68 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 308
  • FIGURE 69 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 308
  • FIGURE 70 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 309
  • FIGURE 71 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 309
  • FIGURE 72 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 336
  • FIGURE 73 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 337
  • FIGURE 74 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 338
  • FIGURE 75 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 339
目次

Global omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 11.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa) - Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global omega-3 ingredients for pharmaceuticals market are

  • Growing demand of functional and supplement food
  • Rising burden of lifestyle diseases leads the demand of omega-3 based products

Market Players:

The key market players for global omega-3 ingredients for pharmaceuticals market are listed below

  • Avestia Pharma
  • Novasep
  • AbbVie Inc.
  • KD Pharma Group
  • BASF SE
  • Corbion NV
  • DSM
  • AstraZeneca
  • GlaxoSmithKline plc.
  • Fresenius Kabi AG
  • Croda International Plc
  • AMARIN CORPORATION
  • ANI Pharmaceuticals, Inc.
  • Epax
  • Strides Pharma Science Limited
  • Pharma Marine AS
  • KinOmega Biopharm Inc.
  • Camber Pharmaceuticals, Inc.
  • Solutex
  • BASF SE

TABLE OF CONTENTS

1 INTRODUCTION 47

  • 1.1 OBJECTIVES OF THE STUDY 47
  • 1.2 MARKET DEFINITION 47
  • 1.3 OVERVIEW OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 47
  • 1.4 CURRENCY AND PRICING 49
  • 1.5 LIMITATIONS 49
  • 1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

  • 2.1 MARKETS COVERED 54
  • 2.2 GEOGRAPHICAL SCOPE 55
  • 2.3 YEARS CONSIDERED FOR THE STUDY 56
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
  • 2.6 MULTIVARIATE MODELLING 61
  • 2.7 SOURCE LIFELINE CURVE 61
  • 2.8 DBMR MARKET POSITION GRID 62
  • 2.9 VENDOR SHARE ANALYSIS 63
  • 2.10 SECONDARY SOURCES 64
  • 2.11 ASSUMPTIONS 64

3 EXECUTIVE SUMMARY 65

  • 3.1 PATENT ANALYSIS 71
    • 3.1.1 DBMR ANALYSIS 71
    • 3.1.2 COUNTRY LEVEL INSIGHTS 71
    • 3.1.3 COMPANY BASED ANALYSIS 73
  • 3.2 PRICING ANALYSIS 74

4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS 75

5 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET 77

  • 5.1 PRICE IMPACT 77
  • 5.2 IMPACT ON DEMAND 77
  • 5.3 IMPACT ON SUPPLY CHAIN 78
  • 5.4 STRATEGIC DECISIONS FOR MANUFACTURERS 78
  • 5.5 CONCLUSION 79

6 MARKET OVERVIEW 80

  • 6.1 DRIVERS 82
    • 6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3 82
    • 6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD 83
    • 6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS 84
    • 6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS 84
  • 6.2 RESTRAINTS 86
    • 6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS 86
    • 6.2.2 HIGH COSTS OF PRODUCTS 86
  • 6.3 OPPORTUNITIES 87
    • 6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3 87
    • 6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS 87
    • 6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES 88
  • 6.4 CHALLENGES 89
    • 6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS 89
    • 6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL 89

7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE 90

  • 7.1 OVERVIEW 91
  • 7.2 MARINE 94
  • 7.3 PLANT 95

8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE 96

  • 8.1 OVERVIEW 97
  • 8.2 DOCOSAHEXAENOIC ACID (DHA) 100
  • 8.3 EICOSAPENTAENOIC ACID (EPA) 101
  • 8.4 ALPHA-LINOLENIC ACID (ALA) 102

9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM 103

  • 9.1 OVERVIEW 104
  • 9.2 LIQUID 107
  • 9.3 DRY 107

10 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS 109

  • 10.1 OVERVIEW 110

  • 10.2 CARDIOVASCULAR DISEASES 113
    • 10.2.1 HYPERLIPIDEMIA 113
    • 10.2.2 STROKES 114
    • 10.2.3 HYPERTENSION 114
    • 10.2.4 OTHERS 114
  • 10.3 CANCER 114
    • 10.3.1 PROSTATE CANCER 115
    • 10.3.2 BREAST CANCER 115
    • 10.3.3 COLORECTAL CANCER 115
    • 10.3.4 OTHERS 115
  • 10.4 NEUROLOGICAL DISORDERS 116
    • 10.4.1 ALZHEIMER'S DISEASE 117
    • 10.4.2 COGNITIVE DISORDERS 117
    • 10.4.3 BIPOLAR DISORDERS 117
    • 10.4.4 SCHIZOPHRENIA 117
    • 10.4.5 OTHERS 117
  • 10.5 AUTOIMMUNE DISEASES 118
    • 10.5.1 RHEUMATOID ARTHRITIS 118
    • 10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 119
    • 10.5.3 TYPE 1 DIABETES 119
    • 10.5.4 OTHERS 119
  • 10.6 BONE & JOINT DISORDERS 119
    • 10.6.1 OSTEOPOROSIS 120
    • 10.6.2 ARTHRITIS 120
    • 10.6.3 OTHERS 120
  • 10.7 SKIN HEALTH 120
    • 10.7.1 ACNE 121
    • 10.7.2 WRINKLES 121
    • 10.7.3 SKIN AGING 121
    • 10.7.4 OTHERS 121
  • 10.8 OPHTHALMIC DISORDERS 122
    • 10.8.1 DRY EYE SYNDROME 122
    • 10.8.2 AGE-RELATED MACULAR DEGENERATION 123
    • 10.8.3 OTHERS 123
  • 10.9 OTHERS 123

11 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE 124

  • 11.1 OVERVIEW 125
  • 11.2 ADULT 128
    • 11.2.1 FEMALE 128
    • 11.2.2 MALE 129
  • 11.3 CHILDREN 129

12 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 130

  • 12.1 OVERVIEW 131
  • 12.2 DIRECT 134
  • 12.3 INDIRECT 134

13 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY 136

  • 13.1 OVERVIEW 137
  • 13.2 NORTH AMERICA 142
    • 13.2.1 U.S. 149
    • 13.2.2 CANADA 153
    • 13.2.3 MEXICO 157
  • 13.3 EUROPE 161
    • 13.3.1 GERMANY 169
    • 13.3.2 U.K 173
    • 13.3.3 FRANCE 177
    • 13.3.4 NETHERLANDS 181
    • 13.3.5 ITALY 185
    • 13.3.6 DENMARK 189
    • 13.3.7 SWEDEN 193
    • 13.3.8 SPAIN 197
    • 13.3.9 SWITZERLAND 201
    • 13.3.10 RUSSIA 205
    • 13.3.11 BELGIUM 209
    • 13.3.12 TURKEY 213
    • 13.3.13 POLAND 217
    • 13.3.14 REST OF EUROPE 221
  • 13.4 ASIA-PACIFIC 222
    • 13.4.1 CHINA 230
    • 13.4.2 JAPAN 235
    • 13.4.3 INDIA 240
    • 13.4.4 SOUTH KOREA 245
    • 13.4.5 AUSTRALIA 249
    • 13.4.6 INDONESIA 253
    • 13.4.7 THAILAND 258
    • 13.4.8 MALAYSIA 263
    • 13.4.9 SINGAPORE 267
    • 13.4.10 VIETNAM 272
    • 13.4.11 NEW ZEALAND 277
    • 13.4.12 PHILIPPINES 282
    • 13.4.13 REST OF ASIA-PACIFIC 287
  • 13.5 SOUTH AMERICA 288
    • 13.5.1 BRAZIL 296
    • 13.5.2 ARGENTINA 301
    • 13.5.3 REST OF SOUTH AMERICA 306
  • 13.6 MIDDLE EAST & AFRICA 307
    • 13.6.1 SOUTH AFRICA 315
    • 13.6.2 UAE 320
    • 13.6.3 SAUDI ARABIA 325
    • 13.6.4 KUWAIT 330
    • 13.6.5 REST OF MIDDLE EAST AND AFRICA 335

14 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE 336

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 336
  • 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 337
  • 14.3 COMPANY SHARE ANALYSIS: EUROPE 338
  • 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 339

15 SWOT ANALYSIS 340

16 COMPANY PROFILE 341

  • 16.1 CRODA INTERNATIONAL PLC 341
    • 16.1.1 COMPANY SNAPSHOT 341
    • 16.1.2 REVENUE ANALYSIS 341
    • 16.1.3 COMPANY SHARE ANALYSIS 342
    • 16.1.4 PRODUCT PORTFOLIO 342
    • 16.1.5 RECENT DEVELOPMENT 342
  • 16.2 CORBION 343
    • 16.2.1 COMPANY SNAPSHOT 343
    • 16.2.2 REVENUE ANALYSIS 343
    • 16.2.3 COMPANY SHARE ANALYSIS 344
    • 16.2.4 PRODUCT PORTFOLIO 344
    • 16.2.5 RECENT DEVELOPMENTS 344

  • 16.3 DSM 345
    • 16.3.1 COMPANY SNAPSHOT 345
    • 16.3.2 REVENUE ANALYSIS 345
    • 16.3.3 COMPANY SHARE ANALYSIS 346
    • 16.3.4 PRODUCT PORTFOLIO 346
    • 16.3.5 RECENT DEVELOPMENTS 346
  • 16.4 KD PHARMA GROUP 347
    • 16.4.1 COMPANY SNAPSHOT 347
    • 16.4.2 COMPANY SHARE ANALYSIS 347
    • 16.4.3 PRODUCT PORTFOLIO 348
    • 16.4.4 RECENT DEVELOPMENTS 349
  • 16.5 STRIDES PHARMA SCIENCE LIMITED 350
    • 16.5.1 COMPANY SNAPSHOT 350
    • 16.5.2 REVENUE ANALYSIS 350
    • 16.5.3 COMPANY SHARE ANALYSIS 351
    • 16.5.4 PRODUCT PORTFOLIO 351
    • 16.5.5 RECENT DEVELOPMENT 351
  • 16.6 BASF SE 352
    • 16.6.1 COMPANY SNAPSHOT 352
    • 16.6.2 REVENUE ANALYSIS 352
    • 16.6.3 PRODUCT PORTFOLIO 353
    • 16.6.4 RECENT DEVELOPMENTS 353
  • 16.7 PHARMA MARINE AS 354
    • 16.7.1 COMPANY SNAPSHOT 354
    • 16.7.2 PRODUCT PORTFOLIO 354
    • 16.7.3 RECENT DEVELOPMENTS 354
  • 16.8 ABBVIE INC. 355
    • 16.8.1 COMPANY SNAPSHOT 355
    • 16.8.2 REVENUE ANALYSIS 355
    • 16.8.3 PRODUCT PORTFOLIO 356
    • 16.8.4 RECENT DEVELOPMENT 356
  • 16.9 AMARIN CORPORATION 357
    • 16.9.1 COMPANY SNAPSHOT 357
    • 16.9.2 REVENUE ANALYSIS 357
    • 16.9.3 PRODUCT PORTFOLIO 358
    • 16.9.4 RECENT DEVELOPMENTS 358
  • 16.10 ANI PHARMACEUTICALS, INC. 359
    • 16.10.1 COMPANY SNAPSHOT 359
    • 16.10.2 REVENUE ANALYSIS 359
    • 16.10.3 PRODUCT PORTFOLIO 360
    • 16.10.4 RECENT DEVELOPMENT 360
  • 16.11 ASTRAZENECA 361
    • 16.11.1 COMPANY SNAPSHOT 361
    • 16.11.2 REVENUE ANALYSIS 361
    • 16.11.3 PRODUCT PORTFOLIO 362
    • 16.11.4 RECENT DEVELOPMENT 362
  • 16.12 AVESTIA PHARMA 363
    • 16.12.1 COMPANY SNAPSHOT 363
    • 16.12.2 PRODUCT PORTFOLIO 363
    • 16.12.3 RECENT DEVELOPMENT 363
  • 16.13 CAMBER PHARMACEUTICALS, INC. 364
    • 16.13.1 COMPANY SNAPSHOT 364
    • 16.13.2 PRODUCT PORTFOLIO 364
    • 16.13.3 RECENT DEVELOPMENTS 364
  • 16.14 EPAX (A SUBSIDIARY OF PELAGIA AS) 365
    • 16.14.1 COMPANY SNAPSHOT 365
    • 16.14.2 REVENUE ANALYSIS 365
    • 16.14.3 PRODUCT PORTFOLIO 366
    • 16.14.4 RECENT DEVELOPMENTS 366
  • 16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG) 367
    • 16.15.1 COMPANY SNAPSHOT 367
    • 16.15.2 REVENUE ANALYSIS 367
    • 16.15.3 PRODUCT PORTFOLIO 368
    • 16.15.4 RECENT DEVELOPMENT 368
  • 16.16 GLAXOSMITHKLINE PLC 369
    • 16.16.1 COMPANY SNAPSHOT 369
    • 16.16.2 REVENUE ANALYSIS 369
    • 16.16.3 PRODUCT PORTFOLIO 370
    • 16.16.4 RECENT DEVELOPMENT 370
  • 16.17 KINOMEGA BIOPHARM INC 371
    • 16.17.1 COMPANY SNAPSHOT 371
    • 16.17.2 PRODUCT PORTFOLIO 371
    • 16.17.3 RECENT DEVELOPMENTS 371
  • 16.18 NOVASEP 372
    • 16.18.1 COMPANY SNAPSHOT 372
    • 16.18.2 REVENUE ANALYSIS 372
    • 16.18.3 PRODUCT PORTFOLIO 373
    • 16.18.4 RECENT DEVELOPMENT 373

  • 16.19 SOLUTEX 374
    • 16.19.1 COMPANY SNAPSHOT 374
    • 16.19.2 PRODUCT PORTFOLIO 374
    • 16.19.3 RECENT DEVELOPMENT 374

17 QUESTIONNAIRE 375

18 RELATED REPORTS 378

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.